Your practitioner will advise on a suitable treatment plan following consultation
In January 2024, the FDA proposed a rule that would prevent BPC-157 from being used in compounding, classifying it alongside other peptides that lack adequate safety and efficacy data for compounded use 3
Cell 136 , 10561072 (2009)
In endothelial cells, BPC-157 activates ERK1/2 signaling, enhancing proliferation, migration, and vascular tube formation through transcription factors including c-Fos, c-Jun, and Egr-1
These injections are given into the muscle and are usually in the form of either hydroxocobalamin or cyanocobalamin, synthetic forms of vitamin B12, which effectively raise blood levels
Use within 60 days of opening for best results